TOCILIZUMAB
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 12 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 12 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after
a break in biological medicine of less than 12 months) or Initial 3 (recommencement
of treatment after a break in biological medicine of more than 12 months) - balance
of supply
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement
of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment
after a break in biological medicine of more than 24 months) - balance of supply
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 24 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement
of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment
after a break in biological medicine of more than 24 months) - balance of supply
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 12 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 12 months)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after
a break in biological medicine of less than 12 months) or Initial 3 (recommencement
of treatment after a break in biological medicine of more than 12 months) - balance
of supply
Manner of administration:Injection
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Manner of administration:Injection
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Manner of administration:Injection
Restriction (Streamlined authority code: 17707)
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment
Manner of administration:Injection
Restriction (Streamlined authority code: 17713)
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment
